Fwd: Antibody-targeted RNase fusion proteins (immunoRNases) for cancer therapy.

---------- Forwarded message ----------
From: HubMed - mesothelioma cancer <rssfwd@rssfwd.com>
Date: Sat, Aug 9, 2008 at 12:44 AM
Subject: Antibody-targeted RNase fusion proteins (immunoRNases) for cancer therapy.
To: mesothelioma77@gmail.com


[1]Curr Pharm Biotechnol. 2008 Jun; 9(3): 231-4
Krauss J, Arndt MA, Dübel S, Rybak SM

Ribonucleases (RNases) of the superfamily A exhibit potent antineoplastic activity yet do not mediate appreciable immunogenicity or non-specific toxicity in both animal models and cancer patients. Ranpirnase (Onconase), the first ribonuclease being evaluated as a therapeutic in humans, has progressed to phase III clinical trials in patients with unresectable mesothelioma. Conjugation of RNases to internalizing tumor-targeting monoclonal antibodies was shown to enhance specific cell killing by several orders of magnitude both in vitro and in animal models. In this review we describe the development and current status of genetically engineered 2(nd) generation immunoRNases as promising novel anti-cancer therapeutics.



___
Source: http://www.hubmed.org/display.cgi?uids=18673289
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: [Pemetrexed]

---------- Forwarded message ----------
From: HubMed - mesothelioma cancer <rssfwd@rssfwd.com>
Date: Sat, Aug 9, 2008 at 12:44 AM
Subject: [Pemetrexed]
To: mesothelioma77@gmail.com


[1]Gan To Kagaku Ryoho. 2008 Jun; 35(6): 1033-8
Sudoh J, Gemma A

Pemetrexed (ALIMTA, LY231514) is a novel, multi targeted antifolate chemotherapy agent that is active in various tumors including mesothelioma, NSCLC, breast, colon and bladder carcinoma. Pemetrexed inhibits several enzymes in the folate pathway including thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Pemetrexed is approved in the United States and a number of European Union countries for use in the treatment of mesothelioma, and the second-line treatment of advanced NSCLC. However, in Japan, pemetrexed was approved for use only in combination with cisplatin in the treatment of mesothelioma in January 2007. This approval was granted on the basis of a phase III trial of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Treatment with pemetrexed plus cisplatin and vitamin supplementation, resulted in superior survival time, time to progression, and response rates compared with treatment with cisplatin alone. In addition, in a phase III trial of pemetrexed versus docetaxel in patients with NSCLC previously treated with chemotherapy, treatment with pemetrexed resulted in clinically equivalent efficacy outcomes, but with significantly fewer side effects including grade 3 or 4 neutropenia , neutropenic fever, and alopecia, compared with docetaxel. Therefore, pemetrexed should be considered a standard treatment option for second-line NSCLC in US and most of EU. Addition of folic acid and vitamin B12 significantly reduced the toxicity of pemetrexed, especially hematologic toxicity and gastrointestinal toxicity. Pemetrexed is the expected agent for use in high risk patients, especially elderly or poor performance status patients.



___
Source: http://www.hubmed.org/display.cgi?uids=18633241
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 />

Fwd: Amentoflavone Inhibits Experimental Tumor Metastasis Through a Regulatory Mechanism Involving MMP-2, MMP-9, Prolyl Hydroxylase, Lysyl Oxidase, VEGF, ERK-1, ERK-2, STAT-1, nm23 and Cytokines in Lung Tissues of C57BL/6 Mice.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Aug 9, 2008 at 12:44 AM
Subject: Amentoflavone Inhibits Experimental Tumor Metastasis Through a Regulatory Mechanism Involving MMP-2, MMP-9, Prolyl Hydroxylase, Lysyl Oxidase, VEGF, ERK-1, ERK-2, STAT-1, nm23 and Cytokines in Lung Tissues of C57BL/6 Mice.
To: mesothelioma77@gmail.com


[1]Immunopharmacol Immunotoxicol. 2008 Aug 5; 1-17
Guruvayoorappan CS, Kuttan G

Amentoflavone has been shown to inhibit tumor metastasis in vivo, but its mechanism of action remains unclear. Here, C57BL/6 mice were injected once with B16F-10 melanoma cells via tail vein followed by amentoflavone treatment (50mg/kg BW) for 10 consecutive days. Twenty-one days after tumor injection, animals were euthanized, and tumor metastasis was found to confine in the lungs. As compared with the tumor controls, amentoflavone treatment significantly lowered the number of lung nodules (p

___
Source: http://www.hubmed.org/display.cgi?uids=18686102
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Acculturation and Familiarity With, Attitudes Towards and Beliefs about Genetic Testing for Cancer Risk Within Latinas in East Harlem, New York City.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Aug 9, 2008 at 12:44 AM
Subject: Acculturation and Familiarity With, Attitudes Towards and Beliefs about Genetic Testing for Cancer Risk Within Latinas in East Harlem, New York City.
To: mesothelioma77@gmail.com


[1]J Genet Couns. 2008 Aug 7;
Sussner KM, Thompson HS, Valdimarsdottir HB, Redd WH, Jandorf L

Recent research underscores the need for increasing use of genetic testing for cancer risk in Latinos. This study examined the influence of acculturation on attitudes, beliefs about and familiarity with genetic testing for cancer risk in a community-based sample of Latinas in East Harlem, New York City (N = 103). Multivariate linear regression models analyzed the relationship of acculturation to: (1) familiarity (2) perceived benefits (3) perceived barriers and (4) concerns about abuses of genetic testing for cancer risk. Controlling for sociodemographic factors, results revealed that with increasing acculturation Latinas were more familiar with genetic testing (beta = 1.62, SE = 0.72, p = 0.03), more likely to cite perceived benefits (beta = 1.67, SE = 0.79, p = 0.04), and less likely to report perceived barriers related to genetic testing (beta = -2.76, SE = 1.64, p = 0.10). Study results may help inform the development of culturally-appropriate health education outreach materials and programs targeted to increase awareness, knowledge and understanding about genetic testing for cancer risk within Latinas.



___
Source: http://www.hubmed.org/display.cgi?uids=18686019
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Developing a codebook to guide content analysis of expressive writing transcripts.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Aug 9, 2008 at 12:44 AM
Subject: Developing a codebook to guide content analysis of expressive writing transcripts.
To: mesothelioma77@gmail.com


[1]Appl Nurs Res. 2008 Aug; 21(3): 165-8
Fonteyn ME, Vettese M, Lancaster DR, Bauer-Wu S

This article describes a team-based approach to the development of a comprehensive codebook for multiple researchers to use during content analysis of the transcripts of the expressive writings of women (in this study, N = 89) with metastatic breast cancer. The codebook structure was developed iteratively by reaching a consensus on the analysis of shared transcripts to create an all-encompassing set of codes, with definitions, inclusion and exclusion criteria, and exemplar text from the transcripts. The Qualitative Solutions and Research International NVivo software program was used to maintain an electronic database of the consensus analysis of transcripts, information about each code, and a detailed log about the process of developing the codebook. The team ultimately created a comprehensive codebook that contained 27 codes with definitions, inclusion and exclusion criteria, and example text. The codes were verified by each team member through reanalysis of a set of shared transcripts that had been previously coded using an earlier version of the codebook. The team met to discuss individual coding and reached a consensus on the final version of the codebook. No new code was identified during the reanalysis, and there was fairly uniform agreement on the coding. The final version of the codebook will be used to guide each team member's individual analysis of the remaining (74) transcripts, which will be divided among the team. Periodic meetings are planned to discuss the individual analysis and to resolve any issue associated with using the codebook. As new codes are identified and agreed upon by the team, they will be added to the codebook. A team-based approach can facilitate the development of a practical and accurate codebook to guide the analysis of a large amount of qualitative data.



___
Source: http://www.hubmed.org/display.cgi?uids=18684411
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: New diagnostic techniques for breast cancer detection.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Aug 9, 2008 at 12:44 AM
Subject: New diagnostic techniques for breast cancer detection.
To: mesothelioma77@gmail.com


[1]Future Oncol. 2008 Aug; 4(4): 501-13
Singh V, Saunders C, Wylie L, Bourke A

Breast imaging has made huge advances in the last decade, and along with newer techniques to diagnose primary breast cancer, many novel methods are being used and look promising in detecting distant metastasis, recurrent disease and assessing response to treatment. Full-field digital mammography optimizes the lesion-background contrast and gives better sensitivity, and it is possible to see through the dense tissues by altering computer windows; this may be particularly useful in younger women with dense breasts. The need for repeat imaging is reduced, with the added advantage of reduced radiation dose to patients. Computer-aided detection systems may help the radiologist in interpretation of both conventional and digital mammograms. MRI has a role in screening women at high risk for breast cancer. It also aids in cancer management by assessing response to treatment and can help in deciding appropriate surgery by providing accurate information on the extent of the tumor. Newer diagnostic techniques such as sestamibi scans, optical imaging and molecular diagnostic techniques look promising, but need more investigation into their use. Their roles will appear clearer in coming years, and they may prove to be of help in further investigating lesions that are indeterminate on standard imaging. Other upcoming techniques are contrast-enhanced mammography and tomosynthesis. These may give additional information in indeterminate lesions, and when used in screening they aid in reducing recall rates, as shown in recent studies. PET/computed tomography has a role in detecting local disease recurrence and distant metastasis in breast cancer patients.



___
Source: http://www.hubmed.org/display.cgi?uids=18684061
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Hereditary diffuse gastric cancer: surgery, surveillance and unanswered questions.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Aug 9, 2008 at 12:44 AM
Subject: Hereditary diffuse gastric cancer: surgery, surveillance and unanswered questions.
To: mesothelioma77@gmail.com


[1]Future Oncol. 2008 Aug; 4(4): 553-9
Cisco RM, Norton JA

Hereditary diffuse gastric cancer (HDGC) is an inherited cancer-susceptibility syndrome characterized by autosomal dominance and high penetrance. In 30-50% of cases, a causative germline mutation in CDH1, the E-cadherin gene, may be identified. Female carriers of CDH1 mutations also have an increased (20-40%) risk of lobular breast cancer. Endoscopic surveillance of patients with CDH1 mutations is ineffective because early foci of HDGC are typically small and underlie normal mucosa. CDH1 mutation carriers are therefore offered the option of prophylactic gastrectomy, which commonly reveals early foci of invasive signet-ring cell cancer. We review recommendations for genetic testing, surveillance and prophylactic surgery in HDGC. Areas for future research are discussed, including development of new screening modalities, optimal timing of prophylactic gastrectomy, identification of additional causative mutations in HDGC, management of patients with CDH1 missense mutations and prevention/early detection of lobular breast cancer in CDH1 mutation carriers.



___
Source: http://www.hubmed.org/display.cgi?uids=18684065
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc